NCT01642667已完成2 期
The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay
Suzhou Landing Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 197 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 197
- 试验地点
- 1
- 主要终点
- angiographic parameters which can demonstrate the myocardium reperfusion, including TIMI flow grade (grade I-III), TIMI frame count (frame) and myocardial blush grade (MBG,grade 0-3).
研究概览
简要总结
The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, ST-segment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had ST-segment elevation, or new left bundle-branch block.
排除标准
- •expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.
研究组 & 干预措施
primary PCI
Placebo Comparator
干预措施: Placebo (Drug)
prouk-PCI
Active Comparator
干预措施: Prourokinase (Drug)
结局指标
主要结局
angiographic parameters which can demonstrate the myocardium reperfusion, including TIMI flow grade (grade I-III), TIMI frame count (frame) and myocardial blush grade (MBG,grade 0-3).
时间窗: 90 minutes after prourokinase bolus
次要结局
- major adverse cardiac events [MACE, defined as the composite of all cause-death, reinfarction, revascularization (including target vessel and non-target vessel revascularizations), or rehospitalization due to new or worsening congestive heart failure](12 month after enrollment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee OsteoarthritisKnee OsteoarthritisNCT04043819Personalized Stem Cells, Inc.125
撤回
2 期
Cri Analog PG1 Effectiveness and Safety in Covid-19Covid19NCT04536363Alonso Vera Torres
已完成
3 期
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)Age-Related Macular DegenerationNCT03668054Laboratorio Elea Phoenix S.A.22
已完成
不适用
Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment MethodSubcutaneous Adipose TissueNCT01853397Solta Medical72
已完成
1 期
Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy SubjectsCicatrixRe-epithelialisationNCT00984854Renovo70